Cigna is dropping GLP-1 coverage. Here's what patients…

The change is specific. Cigna's own employee health plan — the Cigna Group Medical Plan — will no longer cover Wegovy, Zepbound, or other GLP-1 medications when prescribed for weight management. Employees currently on these drugs have until June 30 to obtain a refill under the existing benefit.

Coverage for GLP-1 medications prescribed for type 2 diabetes continues without change. A company spokesperson confirmed this to both Reuters and Becker's Hospital Review: "The change will not apply to those using GLP-1s for diabetes."

The change also does not apply to the commercial health insurance plans Cigna sells to employers and individuals outside the company. Cigna's Evernorth and Express Scripts arms continue to manage GLP-1 benefits for client employers. About 50% of Evernorth's employer clients have chosen to cover GLP-1s for weight loss, according to Becker's Hospital Review.

The spokesperson's explanation was brief: "As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss."

Branded GLP-1 medications for obesity — Wegovy (semaglutide 2.4 mg injectable), Zepbound (tirzepatide injectable), and the newly approved oral Wegovy tablet — are among the most expensive commonly prescribed drugs in the US. Coverage of these medications can add thousands of dollars per employee per year to a health plan's costs.

In 2025 and 2026, cash-pay prices began dropping with the launch of the oral Wegovy pill and Lilly's oral GLP-1 Foundayo (orforglipron), which received FDA approval and launched in 2026. Reuters reported in June 2026 that lowest-dose cash-pay options for these oral formulations start at approximately $149 per month through manufacturer websites. That is considerably lower than earlier branded injectable prices — but still a significant ongoing expense for large employer plans across many employees.

Cigna's employee plan will continue covering older, generic weight-loss medications including phentermine, diethylpropion, benzphetamine, and phendimetrazine. These drugs are less effective than GLP-1s based on available comparative evidence, but they remain a covered alternative for employees who previously had GLP-1 approvals.

Cigna joins a broader employer trend. A 2025 Reuters analysis found many US employers were planning to cut back on GLP-1 coverage as spending on the drugs soared. Cost pressure has not eased in 2026, and Cigna's decision — even if it currently affects only one plan — may influence how other large employers evaluate their own benefits decisions.

If your employer changes or ends GLP-1 coverage for weight loss, there are a few pathways worth understanding — though none is a simple replacement, and all involve tradeoffs.

Manufacturer cash-pay programs. Both Novo Nordisk (NovoCare) and Eli Lilly (LillyDirect) offer direct cash-pay access to their medications. The Cigna document reviewed by Reuters pointed employees toward manufacturer sites as an option. These payments will not count toward your deductible, which means they do not reduce your out-of-pocket exposure under your health plan.

TrumpRx. The federal government's TrumpRx program provides access to certain medications at discounted prices. Cigna specifically referenced TrumpRx in its employee communication. Eligibility criteria and the drug list should be verified directly at trumprx.gov before assuming a GLP-1 is available or covered.

Medicare GLP-1 Bridge (if you qualify). If you are Medicare-eligible, a separate program — the Medicare GLP-1 Bridge — launches July 1, 2026, and provides access to certain GLP-1s for $50 per month for eligible Part D beneficiaries. This is a distinct program covered in a separate article.

Ask about your diagnosis category. If you have type 2 diabetes, cardiovascular disease, or another condition for which a GLP-1 is FDA-approved and covered under your plan, your coverage may continue under a different clinical justification. This is a conversation for your prescriber and pharmacist, not one to assume.

Whether other employers will follow Cigna's lead on their own employee plans is not known. Some large employers have built GLP-1 benefit management programs that include lifestyle support and adherence monitoring — structures designed to manage long-term costs differently than simply offering or removing the benefit.

The broader commercial insurance market is also watching the Medicare GLP-1 Bridge closely. If Medicare data on utilization and outcomes becomes available in 2027, it could inform employer decisions about whether GLP-1 coverage delivers measurable value against its cost.

For employees who stop their GLP-1 medication due to cost, weight regain is a documented risk. Research published in The Lancet eClinicalMedicine in 2026 found that on average, about 60% of weight lost on GLP-1 therapy was regained within one year of stopping. Stopping should be a conversation with your prescriber — not an abrupt decision driven by a benefit change.

• Does my employer health plan cover GLP-1s for weight management — and has anything changed in the last few months?
• If I have type 2 diabetes or a cardiovascular diagnosis, does that change my coverage category?
• What are the cash-pay options for my specific medication, and what will I actually pay?
• If I need to stop my GLP-1 due to cost, what does that transition look like medically?
• Do I qualify for any manufacturer savings programs, TrumpRx, or the Medicare GLP-1 Bridge?

• Your plan's current formulary and any benefit communications from your HR department — these can change mid-year
• Manufacturer cash-pay pricing for your specific drug and dose, which has been changing in 2026
• The Medicare GLP-1 Bridge eligibility criteria if you are on Medicare (launching July 1, 2026)
• Any conversation with your prescriber about a continuity plan if your medication is interrupted

Cigna's decision affects one employer's own employee health plan — about 67,700 people — not the broader commercial insurance market. But it illustrates a real tension: GLP-1 medications have strong clinical evidence for obesity treatment, and they are also expensive enough that health plans are actively looking for ways to manage or reduce that cost.

If your coverage is stable today, that does not guarantee it will stay that way. The conversation to have with your prescriber now is not just about what to take — it's about what you would do if the economics changed. That conversation is worth having before you need it.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Reuters, June 2, 2026. "Cigna drops coverage of GLP-1 obesity drugs for its own employees." reuters.com
• Becker's Hospital Review, June 3, 2026. "Cigna to drop GLP-1 coverage for its employees: Report." beckershospitalreview.com
• The Lancet eClinicalMedicine, 2026. Weight regain after stopping GLP-1 therapy (meta-regression). thelancet.com